-
Clinical and Experimental Rheumatology 2018Fever of unknown origin (FUO) can be caused by a wide group of diseases, and can include both benign and serious conditions. Since the first definition of FUO in the... (Review)
Review
Fever of unknown origin (FUO) can be caused by a wide group of diseases, and can include both benign and serious conditions. Since the first definition of FUO in the early 1960's, several updates to the definition, diagnostic and therapeutic approaches have been proposed. This review outlines a case report of an elderly Italian male patient with high fever and migrating arthralgia who underwent many procedures and treatments before a final diagnosis of Adult-onset Still's disease was achieved. This case report highlights the difficulties in diagnosing certain causes of FUO that requires a very high index of suspicion. The main causes of FUO in paediatric and adult patients will be reviewed here, underlying the fact that a physician should also consider the possibility that a patient with FUO may have a monogenic autoinflammatory disease (AID). The identification of AIDs requires a careful evaluation of both history and clinical details that may reveal important clues to identify the correct aetiology. We also provide a comprehensive account of specific signs and symptoms that could suggest possible diagnoses and guide the work-up of FUO and non-genetic periodic fevers in children.
Topics: Adult; Aged; Algorithms; Arthralgia; Child; Diagnosis, Differential; Exanthema; Fever of Unknown Origin; Humans; Male; Pseudolymphoma; Still's Disease, Adult-Onset
PubMed: 29742054
DOI: No ID Found -
Deutsches Arzteblatt International May 2022
Topics: Anti-Bacterial Agents; Humans; Lyme Disease; Pseudolymphoma
PubMed: 36017988
DOI: 10.3238/arztebl.m2022.0015 -
Dermatology Online Journal May 2020Pseudolymphomatous folliculitis is a benign entity that is included within pseudolymphomas. Because of its rapid clinical growth and suspicious histology it has to be...
Pseudolymphomatous folliculitis is a benign entity that is included within pseudolymphomas. Because of its rapid clinical growth and suspicious histology it has to be differentiated from malignant entities. Given its low frequency, the dermatoscopic characteristics of this entity are not well-characterized and have been described only once previously. We present a middle-aged woman with a facial erythematous plaque of 6 months' evolution, with dermatoscopy in which follicular plugs on an erythematous base were appreciated. The histology showed a dense lymphocytic infiltrate with folliculotropism and follicular alteration, with numerous peripheral histiocytes positive for S100 and CD1a. The lesion partially disappeared after the biopsy, and completely after topical treatment.
Topics: Adult; Dermoscopy; Diagnosis, Differential; Female; Folliculitis; Humans; Middle Aged; Pseudolymphoma; Skin; Skin Diseases
PubMed: 32621704
DOI: No ID Found -
Indian Dermatology Online Journal 2022In dermatology, "pseudo" is often used as a prefix for entities resembling another standard condition, either morphologically or histopathologically. Correspondingly,...
In dermatology, "pseudo" is often used as a prefix for entities resembling another standard condition, either morphologically or histopathologically. Correspondingly, "pseudotumor" is a term encompassing dermatological conditions which are not true proliferations, but either have a clinical resemblance to a known tumor (, Pseudokaposi's sarcoma is actually a non-neoplastic condition) or a histopathological resemblance to one (, pseudo-myogenic hemangioendothelioma named due to a histopathological resemblance between myocytes and tumor cells). Often such a nomenclature can create confusion and unnecessary alarm for both the physicians and the patients. Through this article we attempt to summarise "pseudotumors" in dermatology and classify them into clinical and histopathological "pseudotumors", so as to produce a ready reckoner for this confusing nomenclature.
PubMed: 35287424
DOI: 10.4103/idoj.idoj_226_21 -
Actas Dermo-sifiliograficas Oct 2016The term cutaneous pseudolymphoma refers to benign reactive lymphoid proliferations in the skin that simulate cutaneous lymphomas. It is a purely descriptive term that... (Review)
Review
The term cutaneous pseudolymphoma refers to benign reactive lymphoid proliferations in the skin that simulate cutaneous lymphomas. It is a purely descriptive term that encompasses various reactive conditions with a varied etiology, pathogenesis, clinical presentation, histology, and behavior. We present a review of the different types of cutaneous pseudolymphoma. To reach a correct diagnosis, it is necessary to contrast clinical, histologic, immunophenotypic, and molecular findings. Even with these data, in some cases only the clinical course will confirm the diagnosis, making follow-up essential.
Topics: Angiokeratoma; Diagnosis, Differential; Drug Eruptions; HIV Infections; Humans; Immunophenotyping; Insect Bites and Stings; Lyme Disease; Lymphoma, Non-Hodgkin; Pseudolymphoma; Skin Diseases; Skin Neoplasms; Syphilis; Tattooing; Vaccination
PubMed: 27289134
DOI: 10.1016/j.ad.2016.05.003 -
Archives of Pathology & Laboratory... Nov 2018Composite lymphomas have been defined as 2 distinct subtypes of lymphoma occurring at a single anatomic site. Composite lymphomas limited to the skin are a rare... (Review)
Review
Composite lymphomas have been defined as 2 distinct subtypes of lymphoma occurring at a single anatomic site. Composite lymphomas limited to the skin are a rare occurrence and pose a unique challenge. Many reported cases within the skin are combined B-cell and T-cell lymphomas, typically mycosis fungoides and a low-grade B-cell lymphoma. These cases are challenging to recognize because lymphoid infiltrates within the skin often include a mixed population of B cells and T cells. In particular, reactive lymphoid proliferations (pseudolymphomas), primary cutaneous low-grade B-cell lymphomas, and primary cutaneous CD4 T-cell lymphoproliferative disorder may show nearly equal numbers of B cells and T cells. In order to exclude these possibilities, overwhelming evidence in support of each lymphoma is helpful, including abnormal architecture, cytology, and immunophenotype, as well as molecular genetic evidence of clonality.
Topics: Composite Lymphoma; Humans; Lymphoma, B-Cell; Lymphoma, T-Cell; Skin Neoplasms
PubMed: 30407855
DOI: 10.5858/arpa.2018-0283-RA -
Indian Journal of Dermatology 2022
PubMed: 36998855
DOI: 10.4103/ijd.ijd_518_22 -
Alpha Psychiatry Jan 2023
PubMed: 36879993
DOI: 10.5152/alphapsychiatry.2023.221037 -
Journal of Neuroinflammation Jul 2023Immune inflammatory responses play an important role in spinal cord injury (SCI); however, the beneficial and detrimental effects remain controversial. Many studies have...
BACKGROUND
Immune inflammatory responses play an important role in spinal cord injury (SCI); however, the beneficial and detrimental effects remain controversial. Many studies have described the role of neutrophils, macrophages, and T lymphocytes in immune inflammatory responses after SCI, although little is known about the role of B lymphocytes, and immunosuppression can easily occur after SCI.
METHODS
A mouse model of SCI was established, and HE staining and Nissl staining were performed to observe the pathological changes. The size and morphology of the spleen were examined, and the effects of SCI on spleen function and B cell levels were detected by flow cytometry and ELISA. To explore the specific mechanism of immunosuppression after SCI, B cells from the spleens of SCI model mice were isolated using magnetic beads and analyzed by 4D label-free quantitative proteomics. The level of inflammatory cytokines and iron ions were measured, and the expression of proteins related to the Tom20 pathway was quantified by western blotting. To clarify the relationship between iron ions and B cell pyroptosis after SCI, we used FeSO and CCCP, which induce oxidative stress to stimulate SCI, to interfere with B cell processes. siRNA transfection to knock down Tom20 (Tom20-KD) in B cells and human B lymphocytoma cell was used to verify the key role of Tom20. To further explore the effect of iron ions on SCI, we used deferoxamine (DFO) and iron dextran (ID) to interfere with SCI processes in mice. The level of iron ions in splenic B cells and the expression of proteins related to the Tom20-Bax-caspase-gasdermin E (GSDME) pathway were analyzed.
RESULTS
SCI could damage spleen function and lead to a decrease in B cell levels; SCI upregulated the expression of Tom20 protein in the mitochondria of B cells; SCI could regulate the concentration of iron ions and activate the Tom20-Bax-caspase-GSDME pathway to induce B cell pyroptosis. Iron ions aggravated CCCP-induced B cell pyroptosis and human B lymphocytoma pyroptosis by activating the Tom20-Bax-caspase-GSDME pathway. DFO could reduce inflammation and promote repair after SCI by inhibiting Tom20-Bax-caspase-GSDME-induced B cell pyroptosis.
CONCLUSIONS
Iron overload activates the Tom20-Bax-caspase-GSDME pathway after SCI, induces B cell pyroptosis, promotes inflammation, and aggravates the changes caused by SCI. This may represent a novel mechanism through which the immune inflammatory response is induced after SCI and may provide a new key target for the treatment of SCI.
Topics: Animals; Humans; Mice; B-Lymphocytes; bcl-2-Associated X Protein; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Caspases; Gasdermins; Inflammation; Iron; Pseudolymphoma; Pyroptosis; Spinal Cord Injuries
PubMed: 37480037
DOI: 10.1186/s12974-023-02848-0 -
Acta Dermato-venereologica Mar 2018Cutaneous pseudolymphoma (CPL) is a reactive polyclonal T- or B-cell lymphoproliferative process. CPL may appear as localized or disseminated skin lesions. While most... (Review)
Review
Cutaneous pseudolymphoma (CPL) is a reactive polyclonal T- or B-cell lymphoproliferative process. CPL may appear as localized or disseminated skin lesions. While most cases of CPL are idiopathic, they may also occur as a response to, for example, contact dermatitis, arthropod reactions, and bacterial infections. CPL can be classified based on its clinical features, but all variants have similar histopathological patterns of either predominantly B-cell infiltrates, T-cell infiltrates, or mixed T/B-cell infiltrates. The prognosis of CPL is good, but the underlying disease process should be taken into account. If an antigenic stimulus is identified, it should be removed. In patients with idiopathic CPL, a close follow-up control strategy should be adopted. The aim of this systematic review is to summarize all reported treatments for CPL. The review was based on articles from the PubMed database, using the query "skin pseudolymphoma treatment", English and German, about "human" subjects, and published between 1990 and 2015 documenting adequate treatment and/or aetiology. Mainly individual case reports and small case series were found. Treatment options include topical and intralesional agents, systemic agents, and physical modalities. The final part of the review proposes a treatment algorithm for CPL according to each aetiology, based on the literature of the last 25 years. Future research should focus on randomized controlled trials and studies on long-term outcomes, which were not identified in the current review.
Topics: B-Lymphocytes; Dermatologic Agents; Dermatologic Surgical Procedures; Humans; Predictive Value of Tests; Pseudolymphoma; Risk Factors; Skin; Skin Diseases; T-Lymphocytes; Treatment Outcome
PubMed: 29136262
DOI: 10.2340/00015555-2841